Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility
Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility
复制标题
DOI：
10.3109/00365521.2012.654402
复制
发表时间：
2012-04-01
影响因子：
1.9
通讯作者：
Moshiree, Baharak
中科院分区：
文献类型：
--
作者：
Chini, Payam;Toskes, Phillip P.;Moshiree, Baharak
目标。目的：探讨阿奇霉素(AZI)对胃肠动力障碍(GID)患者小肠运动功能的影响。材料和方法。对连续21例患者的测压数据进行了回顾。只有那些胃轻瘫和十二指肠测压标准定义的小肠运动障碍的患者被纳入。记录压力曲线的三个阶段：红霉素(ERY)和AZI给药后的基线期、喂养状态和餐后。测量的参数包括活动前沿和移行运动复合体(MMC)的数量和特征，包括收缩持续时间、幅度和频率。使用重复测量方差分析对数据进行分析，以比较每种药物。结果。AZI诱导的十二指肠MMC数明显多于ERY(AZI组18例，ERY组10例)。在MMCs的幅度和每分钟循环次数方面，Azi和ERY之间没有显著差异。AZI组活动峰平均持续时间较ERY组长(AZI平均18.5min，ERY平均9.7min，p<；0.02)。结论。在GID患者中，AZI比ERY更频繁地在胃窦部诱发活动前锋，随后是十二指肠收缩。AZI有望成为治疗小肠运动障碍的促进剂。
Objective. To investigate the effect of azithromycin (AZI) on small bowel activity in patients with gastrointestinal dysmotility (GID). Material and methods. Manometric data on a consecutive series of 21 patients was reviewed. Only those patients with gastroparesis and small bowel dysmotility as defined by antroduodenal manometric criteria were included. Pressure profiles were recorded in three stages: baseline period, fed state and postprandial after administration of erythromycin (ERY) and AZI. The measured parameters included the number and characteristics of activity fronts and migrating motor complexes (MMCs) including duration, amplitude and frequency of contractions. The data were analyzed using repeated measures analysis of variance for comparison of each medication. Results. AZI induced more MMCs in the duodenum with origin of activity fronts in the antrum than did ERY (18 patients with AZI, 10 patients with ERY). No significant difference between AZI and ERY was seen with respect to the amplitude of MMCs or number of cycles per minute. The average duration of activity fronts was longer with AZI compared with ERY (AZI mean 18.5 min, ERY mean 9.7 min, p < 0.02). Conclusions. AZI induces activity fronts in the antrum followed by duodenal contractions more frequently than ERY in patients with GID. AZI potentially promises to be a prokinetic for treatment of small bowel dysmotility.